January 28, 2024
EVerMed Inc. has raised 180 million yen through a third-party allotment of new shares to Nissay Capital No. 13 Investment Limited Partnership (Chiyoda-ku, Tokyo; General Partner: NISSAY CAPITAL CO.,LTD., President and CEO Kosuke Ueda ) .
EVerMed is a startup company originating from the Jikei University School of Medicine that aims to apply extracellular vesicles to medical applications.
Including this capital increase, the total amount raised in the seed round has reached approximately 510 million yen.
We are currently developing bronchial epithelial cell-derived extracellular vesicles (EM-001) for the treatment of idiopathic pulmonary fibrosis (IPF) and pulmonary fibroblast-derived extracellular vesicles (EM-002) for the treatment of COPD and are also developing technologies to create new pipelines.